Download video

Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter's transformation

88 views

VJHemOnc – Video Journal of Hematology & HemOnc

1 year ago

Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter's transformation

Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter's transformation

Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter's transformation
1:52
Evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in Richter's transformation
by VJHemOnc – Video Journal of Hematology \& HemOnc
Phase II study of fixed-duration obinutuzumab, ibrutinib \& venetoclax in elderly patients with RT
2:03
Phase II study of fixed-duration obinutuzumab, ibrutinib \& venetoclax in elderly patients with RT
by VJHemOnc – Video Journal of Hematology \& HemOnc
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
1:25
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
by OncLive
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
2:43
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
1:36
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Ibrutinib plus venetoclax followed by MRD-guided ibrutinib plus obinutuzumab in first line CLL
4:36
Ibrutinib plus venetoclax followed by MRD-guided ibrutinib plus obinutuzumab in first line CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
1:46
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
EHA22: TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +\/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN ...
10:20
EHA22: TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +\/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN ...
by Oncoletter
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
1:36
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL
4:44
7-year update on a Phase II trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
GLOW: Assessing ibrutinib plus venetoclax in CLL
1:54
GLOW: Assessing ibrutinib plus venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
0:49
Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
by VJHemOnc – Video Journal of Hematology \& HemOnc
Ibrutinib, Venetoclax \& Obinutuzumab to Treat Chronic Lymphocytic Leukemia (CLL) - Dr. Woyach
15:16
Ibrutinib, Venetoclax \& Obinutuzumab to Treat Chronic Lymphocytic Leukemia (CLL) - Dr. Woyach
by CLL Society
Ibrutinib, Venetoclax, Obinutuzumab for Richter Transformation - Dr. Tamar Tadmor
7:12
Ibrutinib, Venetoclax, Obinutuzumab for Richter Transformation - Dr. Tamar Tadmor
by CLL Society
CLARITY: a Phase 2 trial using venetoclax and ibrutinib
1:00
CLARITY: a Phase 2 trial using venetoclax and ibrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLL
1:50
Insights into the MAJIC study: acalabrutinib + venetoclax vs venetoclax + obinutuzumab in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc